Search Results - "Hurtig, H I"

DLB and PDD boundary issues : Diagnosis, treatment, molecular pathology, and biomarkers by LIPPA, C. F, DUDA, J. E, FAHN, S, FARMER, J. M, GALASKO, D, GALVIN, J. E, GOETZ, C. G, GROWDON, J. H, GWINN-HARDY, K. A, HARDY, J, HEUTINK, P, IWATSUBO, T, GROSSMAN, M, KOSAKA, K, LEE, V. M.-Y, LEVERENZ, J. B, MASLIAH, E, MCKEITH, I. G, NUSSBAUM, R. L, OLANOW, C. W, RAVINA, B. M, SINGLETON, A. B, TANNER, C. M, HURTIG, H. I, TROJANOWSKI, J. Q, WSZOLEK, Z. K, AARSLAND, D, BOEVE, B. F, BROOKS, D. J, DICKSON, D. W, DUBOIS, B, EMRE, M

“…For more than a decade, researchers have refined criteria for the diagnosis of dementia with Lewy bodies (DLB) and at the same time have recognized that…”
Get full text

Glucocerebrosidase mutations are an important risk factor for lewy body disorders by GOKER-ALPAN, O, GIASSON, B. I, EBLAN, M. J, NGUYEN, J, HURTIG, H. I, LEE, V. M.-Y, TROJANOWSKI, J. Q, SIDRANSKY, E

“…The synucleinopathies are neurodegenerative disorders defined by inclusions composed of aberrantly fibrillized alpha-synuclein, but factors contributing to…”
Get full text

[99mTc]TRODAT-1 SPECT imaging correlates with odor identification in early Parkinson disease by SIDEROWF, A, NEWBERG, A, DUDA, J. E, WEINTRAUB, D, MOBERG, P. J, CHOU, K. L, LLOYD, M, COLCHER, A, HURTIG, H. I, STERN, M. B, DOTY, R. L, MOZLEY, P. D, WINTERING, N

“…In vivo imaging of the dopamine transporter with [99mTc]TRODAT-1 (TRODAT) and olfactory testing have both been proposed as potential biomarkers in Parkinson…”
Get full text

Grammatical and resource components of sentence processing in Parkinson's disease: An fMRI study by GROSSMAN, M, COOKE, A, DEVITA, C, LEE, C, ALSOP, D, DETRE, J, GEE, J, CHEN, W, STERN, M. B, HURTIG, H. I

“…Sentence comprehension requires linguistic processing as well as cognitive resources such as working memory (WM) and information-processing speed (IPS). The…”
Get full text

Oxidative Damage Linked to Neurodegeneration by Selective α-Synuclein Nitration in Synucleinopathy Lesions by Giasson, Benoit I., Duda, John E., Ian V. J. Murray, Chen, Qiping, Souza, José M., Hurtig, Howard I., Ischiropoulos, Harry, Trojanowski, John Q., Virginia M.-Y. Lee

“…Aggregated α-synuclein proteins form brain lesions that are hallmarks of neurodegenerative synucleinopathies, and oxidative stress has been implicated in the…”
Get full text

Longitudinal decline in autopsy-defined frontotemporal lobar degeneration by GROSSMAN, M, XIE, S. X, HURTIG, H. I, FORMAN, M. S, LEE, V. M.-Y, TROJANOWSKI, J. Q, LIBON, D. J, WANG, X, MASSIMO, L, MOORE, P, VESELY, L, BERKOWITZ, R, CHATTERJEE, A, COSLETT, H. B

“…The natural history of patients with pathologically proven frontotemporal lobar degeneration (FTLD) is important from clinical and biologic perspectives, but…”
Get full text

TDP-43 pathology occurs infrequently in multiple system atrophy by Geser, F., Malunda, J. A., Hurtig, H. I., Duda, J. E., Wenning, G. K., Gilman, S., Low, P. A., Lee, V. M.-Y., Trojanowski, J. Q.

“…F. Geser, J. A. Malunda, H. I. Hurtig, J. E. Duda, G. K. Wenning, S. Gilman, P. A. Low, V. M.‐Y. Lee and J. Q. Trojanowski (2011) Neuropathology and Applied…”
Get full text

Cognitive and motor assessment in autopsy-proven corticobasal degeneration by MURRAY, R, NEUMANN, M, GORNO-TEMPINI, M. L, LEE, V. M.-Y, TROJANOWSKI, J. Q, GROSSMAN, M, FORMAN, M. S, FARMER, J, MASSIMO, L, RICE, A, MILLER, B. L, JOHNSON, J. K, CLARK, C. M, HURTIG, H. I

Get full text

Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson's disease by HURTIG, H. I, TROJANOWSKI, J. Q, ARNOLD, S. E, GALVIN, J, EWBANK, D, SCHMIDT, M. L, LEE, V. M.-Y, CLARK, C. M, GLOSSER, G, STERN, M. B, GOLLOMP, S. M

“…Dementia is a frequent complication of idiopathic parkinsonism or PD, usually occurring later in the protracted course of the illness. The primary site of…”
Get full text

Neurodegeneration with Brain Iron Accumulation, Type 1 Is Characterized by α-, β-, and γ-Synuclein Neuropathology by Galvin, James E., Giasson, Benoit, Hurtig, Howard I., Lee, Virginia M.-Y., Trojanowski, John Q.

“…Neurodegeneration with brain iron accumulation, type 1 (NBIA 1), or Hallervorden-Spatz syndrome, is a rare neurodegenerative disorder characterized clinically…”
Get full text

Atomoxetine for depression and other neuropsychiatric symptoms in Parkinson disease by Weintraub, D, Mavandadi, S, Mamikonyan, E, Siderowf, A D, Duda, J E, Hurtig, H I, Colcher, A, Horn, S S, Nazem, S, Ten Have, T R, Stern, M B

“…Depression and antidepressant use, especially selective serotonin reuptake inhibitors (SSRIs), are common in Parkinson disease (PD). The objective of this…”
Get full text

Bilateral olfactory dysfunction in early stage treated and untreated idiopathic Parkinson's disease by Doty, R L, Stern, M B, Pfeiffer, C, Gollomp, S M, Hurtig, H I

“…Decreased olfactory function is among the first signs of idiopathic Parkinson's disease (PD). Whether such dysfunction is present to the same degree on both…”
Get full text

MR signal abnormalities at 1.5 T in Alzheimer's dementia and normal aging by Fazekas, F, Chawluk, JB, Alavi, A, Hurtig, HI, Zimmerman, RA

“…The type, frequency, and extent of MR signal abnormalities in Alzheimer's disease and normal aging are a subject of controversy. With a 1.5-MR unit we studied…”
Get full text

Hippocampal subfield pathologic burden in Lewy body diseases vs. Alzheimer’s disease by Coughlin, D. G., Ittyerah, R., Peterson, C., Phillips, J. S., Miller, S., Rascovsky, K., Weintraub, D., Siderowf, A. D., Duda, J. E., Hurtig, H. I., Wolk, D. A., McMillan, C. T., Yushkevich, P. A., Grossman, M., Lee, E. B., Trojanowski, J. Q., Irwin, D. J.

“…Lewy body diseases (LBD) are characterized by alpha‐synuclein (SYN) pathology, but co‐morbid Alzheimer’s disease pathology is common and the relationship…”
Get full text

Novel CSF biomarkers for frontotemporal lobar degenerations by Hu, W T, Chen-Plotkin, A, Grossman, M, Arnold, S E, Clark, C M, Shaw, L M, McCluskey, L, Elman, L, Hurtig, H I, Siderowf, A, Lee, V M-Y, Soares, H, Trojanowski, J Q

“…To identify antemortem CSF diagnostic biomarkers that can potentially distinguish between the 2 main causes of frontotemporal lobar degeneration (FTLD), i.e.,…”
Get full text

Problems with Current Pharmacologic Treatment of Parkinson's Disease by Hurtig, Howard I.

“…For the past 30 years levodopa (LD) has been the pharmacologic standard of care for treating idiopathic parkinsonism (Parkinson's disease or PD), a…”
Get full text

Cognitive and motor assessment in autopsy-proven corticobasal degeneration by Murray, R, Neumann, M, Forman, M S, Farmer, J, Massimo, L, Rice, A, Miller, B L, Johnson, J K, Clark, C M, Hurtig, H I, Gorno-Tempini, M L, Lee, V M-Y, Trojanowski, J Q, Grossman, M

“…To investigate the clinical features of autopsy-proven corticobasal degeneration (CBD). We evaluated symptoms, signs, and neuropsychological deficits…”
Get full text

Diagnostic accuracy of [ 99mTc]TRODAT-1 SPECT imaging in early Parkinson's disease by Chou, K.L, Hurtig, H.I, Stern, M.B, Colcher, A, Ravina, B, Newberg, A, Mozley, P.D, Siderowf, A

“…We evaluated the diagnostic accuracy of SPECT imaging using [ 99mTc]TRODAT-1 (TRODAT), a relatively inexpensive technetium-labeled dopamine transporter ligand,…”
Get full text

Multicenter, placebo-controlled trial of cabergoline taken once daily in the treatment of Parkinson's disease by HUTTON, J. T, KOLLER, W. C, MUENTER, M. D, ADLER, C. H, MORRIS, J. L, AHLSKOG, J. E, PAHWA, R, HURTIG, H. I, STERN, M. B, HINER, B. C, LIEBERMAN, A, RODNITZKY, R. L, WATERS, C. H

“…Cabergoline is a dopaminergic agonist relatively specific for the D2 receptor and much longer-acting than other dopamine agonists. We conducted a randomized,…”
Get full text

Loss of dopamine D2 receptors in alzheimer's disease with parkinsonism but not Parkinson's or Alzheimer's disease by JOYCE, J. N, MURRAY, A. M, HURTIG, H. I, GOTTLIEB, G. L, TROJANOWSKI, J. Q

“…A significant proportion of patients with Alzheimer's disease (AD) exhibit extrapyramidal features that are referred to as parkinsonism (AD/Park) to…”
Get full text